Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Clinical trial NCT03260894 · COMPLETED

Trial details

NCT number: NCT03260894
Sponsor: Incyte Corporation
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Renal Cell Carcinoma (RCC)

Start date: 2017-12-07
Primary completion: 2018-08-22
Enrollment: 129

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.